Partial dopamine D2/serotonin 5-HT1a receptor agonists as new therapeutic agents

Open Neuropsychopharmacology Journal

Volumn 3, Issue , 2010, Pages 1-12

  Etievant, Adeline ^a   Bétry, Cécile ^a   Haddjeri, Nasser ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Dopamine; Partial agonists; Pschiatric disorders; Serotonin

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; BUSPIRONE; CITALOPRAM; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GEPIRONE; HALOPERIDOL; IPSAPIRONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TANDOSPIRONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

AKATHISIA; ARTICLE; ASTHENIA; BIPOLAR DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; METABOLIC DISORDER; MIXED MANIA AND DEPRESSION; MOOD DISORDER; MOTOR DYSFUNCTION; NAUSEA; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; RESTLESSNESS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 77958168181     PISSN: None     EISSN: 18765238     Source Type: Journal    
DOI: 10.2174/1876523801003010001     Document Type: Article

References (203)

1. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64(3): 327-37.
2. Kalivas PW. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007; 9(4): 389-97.
3. Laviolette SR. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia? Schizophr Bull 2007; 33(4): 971-81.
4. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005; 20(1): 15-27.
5. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28 (Suppl 1): 53-67.
6. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109(3): 411-20.
7. Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol 2001; 86(4): 376-80.
8. Etievant A, Betry C, Arnt J, Haddjeri N. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neurosci Lett 2009; 460(1): 82-6.
9. Adell A, Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 2004; 28(4): 415-31.
10. Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 2000; 23 (Suppl 10): S28-33.
11. Millan MJ, Gobert A, Newman-Tancredi A, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)- receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293(3): 1048-62.
12. Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization. Neuroscience 1983; 10(2): 301-15.
13. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003; 6(9): 968-73.
14. Gonon FG. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 1988; 24(1): 19-28.
15. Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964; 20(7): 398-9.
16. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992; 72(1): 165-229.
17. Wiklund L, Bjorklund A. Mechanisms of regrowth in the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. II. Fluorescence histochemical observations. Brain Res 1980; 191(1): 109-27.
18. Descarries L, Watkins KC, Garcia S, Beaudet A. The serotonin neurons in nucleus raphe dorsalis of adult rat: a light and electron microscope radioautographic study. J Comp Neurol 1982; 207(3): 239-54.
19. Baker PC, Hoff KM. Chronic citalopram action and the maturing mouse brain's indoleamine levels. Gen Pharmacol 1990; 21(5): 703-7.
20. Moss MS, Basbaum AI. The peptidergic organization of the cat periaqueductal gray. II. The distribution of immunoreactive substance P and vasoactive intestinal polypeptide. J Neurosci 1983; 3(7): 1437-49.
21. Descarries L, Berthelet F, Garcia S, Beaudet A. Dopaminergic projection from nucleus raphe dorsalis to neostriatum in the rat. J Comp Neurol 1986; 249(4): 511-20, 484-5.
22. Harandi M, Aguera M, Gamrani H, et al. gamma-Aminobutyric acid and 5-hydroxytryptamine interrelationship in the rat nucleus raphe dorsalis: combination of radioautographic and immunocytochemical techniques at light and electron microscopy levels. Neuroscience 1987; 21(1): 237-51.
23. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957; 12(3): 323-8.
24. Humphrey PP, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993; 14(6): 233-6.
25. Aghajanian GK, Lakoski JM. Hyperpolarization of serotonergic neurons by serotonin and LSD: studies in brain slices showing increased K+ conductance. Brain Res 1984; 305(1): 181-5.
26. Rueter LE, Fornal CA, Jacobs BL. A critical review of 5-HT brain microdialysis and behavior. Rev Neurosci 1997; 8(2): 117-37.
27. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician 2007; 75(12): 1821-9.
28. Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci USA 1999; 96(24): 13591-3.
29. Walker E, Kestler L, Bollini A, Hochman KM. Schizophrenia: etiology and course. Annu Rev Psychol 2004; 55: 401-30.
30. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 2001; 41: 237-60.
31. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261(5562): 717-9.
32. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000; 97(14): 7673-5.
33. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291-314.
34. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008; 22 (Suppl. 2): 70-5.
35. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251(1): 238-46.
36. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10(1): 79-104.
37. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28(8): 1400-11.
38. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 2009; 23(2): 177-89.
39. Assie MB, Mnie-Filali O, Ravailhe V, et al. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. Eur J Pharmacol 2009; 607(1-3): 74-83.
40. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 2004; 111(2): 113-26.
41. Gyertyán I, Kiss B, Sághy K, et al. Pharmacological profile of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist atypical antipsychotic. Papers of the 19th ECNP Congress 2006; 16 (Suppl 4): S432.
42. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 1998; 43(1): 2-11.
43. Natesan S, Svensson KA, Reckless GE, et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)- OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychoticlike efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 2006; 318(2): 810-8.
44. Hand TH, Hu XT, Wang RY. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 1987; 415(2): 257-69.
45. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 1997; 20(1): 31-7.
46. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3(8): 1607-19.
47. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 221(4615): 1054-7.
48. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 2007; 191(3): 745-58.
49. Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007; 190(3): 373-82.
50. Chernoloz O, El Mansari M, Blier P. Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl) 2009; 206(2): 335-44.
51. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302(1): 381-9.
52. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(8): 1213-9.
53. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41(1): 1-24.
54. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 2005; 52 (Suppl): 284-90.
55. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3- Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274(1): 329-36.
56. Westerink BH, de Boer P, de Vries JB, Kruse CG, Long SK. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 1998; 361(1): 27-33.
57. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005; 315(1): 265-72.
58. Karoum F, Egan MF. Dopamine release and metabolism in the rat frontal cortex, nucleus accumbens, and striatum: a comparison of acute clozapine and haloperidol. Br J Pharmacol 1992; 105(3): 703-7.
59. Santiago M, Machado A, Cano J. Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur J Pharmacol 1993; 239(1-3): 83-91.
60. King D, Zigmond MJ, Finlay JM. Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell. Neuroscience 1997; 77(1): 141-53.
61. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483(1): 45-53.
62. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004; 493(1-3): 75-83.
63. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 2008; 195(1): 98-102.
64. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991; 48(4): 355-63.
65. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15(5): 442-55.
66. Kasper S, Tauscher J, Willeit M, et al. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology. World J Biol Psychiatry 2002; 3(3): 133-46.
67. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000; 295(3): 853-61.
68. Frankle WG, Lombardo I, Kegeles LS, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl) 2006; 189(2): 155-64.
69. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 1998; 355(2-3): 245-56.
70. Prinssen EP, Kleven MS, Koek W. Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology (Berl) 1996; 128(2): 191-7.
71. Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11(3): 193-7.
72. Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol 2001; 21(4): 454-5.
73. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990; 54(5): 1755-60.
74. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999; 288(2): 774-81.
75. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008; 172: 177-97.
76. Tanda G, Carboni E, Frau R, Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 1994; 115(1-2): 285-8.
77. Kuroki T, Ichikawa J, Dai J, Meltzer HY. R(+)-8-OH-DPAT, a 5- HT1A receptor ago]nist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res 1996; 743(1-2): 357-61.
78. Sakaue M, Somboonthum P, Nishihara B, et al. Postsynaptic 5- hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 2000; 129(5): 1028-34.
79. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000; 48(3): 229-37.
80. Arborelius L, Nomikos GG, Hacksell U, Svensson TH. (R)-8-OH- DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 1993; 148(4): 465-6.
81. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002; 956(2): 349-57.
82. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76(5): 1521-31.
83. Volonte M, Monferini E, Cerutti M, Fodritto F, Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 1997; 69(1): 182-90.
84. Rollema H, Lu Y, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997; 338(2): R3-5.
85. Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res 2004; 1023(1): 54-63.
86. Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005; 25(47): 10831-43.
87. Yasuno F, Suhara T, Nakayama T, et al. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry 2003; 160 (2): 334-40.
88. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15(1): 37-46.
89. Siris SG. Depression in schizophrenia: perspective in the era of Atypical antipsychotic agents. Am J Psychiatry 2000; 157(9): 1379-89.
90. Keck PE Jr., Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61 (Suppl. 3): 4-9.
91. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53(3): 193-203.
92. Depoortere R, Boulay D, Perrault G, et al. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 2003; 28(11): 1889-902.
93. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007; 8(7): 539-54.
94. Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008; 55(6): 1056-65.
95. Wadenberg ML, Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm Gen Sect 1991; 83(1-2): 43-53.
96. Wadenberg ML, Hillegaart V. Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OHDPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 1995; 34(5): 495-9.
97. Prinssen EP, Kleven MS, Koek W. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl) 1999; 144(1): 20-9.
98. Christoffersen CL, Meltzer LT. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(din-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 1998; 18(5): 399-402.
99. Bardin L, Auclair A, Kleven MS, et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 2007; 18(2): 103-18.
100. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001; 158(10): 1722-5.
101. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 420 (Suppl): 21-7.
102. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358(1): 55-68.
103. Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular Med 2004; 5(1): 27-40.
104. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15(7): 220-6.
105. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a metaanalysis of monoamine depletion studies. Mol Psychiatry 2007; 12(4): 331-59.
106. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114(4): 559-65.
107. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7(2): 137-51.
108. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13(2): 57-66.
109. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19(9): 378-83.
110. Nestler EJ, Gould E, Manji H, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002; 52(6): 503-28.
111. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008; 33(9): 2080-92.
112. Schechter LE, Ring RH, Beyer CE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005; 2(4): 590-611.
113. Mnie-Filali O, Lambas-Senas L, Zimmer L, Haddjeri N. 5-HT7 receptor antagonists as a new class of antidepressants. Drug News Perspect 2007; 20(10): 613-8.
114. Lucas G, Rymar VV, Du J, et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007; 55(5): 712-25.
115. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatmentresistant depression. J Clin Psychiatry 2009; 70(3): 387-96.
116. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66(10): 1289-97.
117. Thase ME, Corya SA, Osuntokun O, et al. A randomized, doubleblind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68 (2): 224-36.
118. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31(11): 2505-13.
119. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatmentresistant depression: an extended follow-up. Depress Anxiety 2004; 20 (3): 131-8.
120. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161(3): 564-6.
121. Worthington JJ, 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20(1): 9-11.
122. Sheffrin M, Driscoll HC, Lenze EJ, et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J Clin Psychiatry 2009; 70(2): 208-13.
123. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68(6): 843-53.
124. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol 2008; 28(2): 156-65.
125. Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009; 31(5): 478-83.
126. Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 1989; 96(2): 283-90.
127. de Montigny C, Blier P, Chaput Y. Electrophysiologicallyidentified serotonin receptors in the rat CNS. Effect of antidepressant treatment. Neuropharmacology 1984; 23(12B): 1511-20.
128. Haddjeri N, Ortemann C, de Montigny C, Blier P. Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. Eur Neuropsychopharmacol 1999; 9(5): 427-40.
129. Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987; 1(5): 470-80.
130. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004; 29(4): 252-65.
131. Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatry 1991; 52 (Suppl): 24-31.
132. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20(24): 9104-10.
133. Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999; 21 (Suppl 2): 46S-51S.
134. Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998; 51(3): 255-66.
135. Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 1998; 18(23): 10150-6.
136. Haddjeri N, Szabo ST, de Montigny C, Blier P. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology 2000; 22(4): 346-56.
137. Haddjeri N, De Montigny C, Curet O, Blier P. Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. Eur J Pharmacol 1998; 343(2-3): 179-92.
138. Andrade R, Nicoll RA. Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1987; 336(1): 5-10.
139. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979; 136(9): 1184-7.
140. Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry 2008; 69(4): 571-7.
141. Robinson DS, Rickels K, Feighner J, et al. Clinical effects of the 5- HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10 (Suppl 3): 67S-76S.
142. Stahl SM, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsychopharmacol 1998; 1(1): 11-18.
143. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009; 42(3): 57-90.
144. Jenkins SW, Robinson DS, Fabre LF, Jr., Andary JJ, Messina ME, Reich LA. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990; 10 (Suppl 3): 77S-85S.
145. Sakr A, Andheria M. Pharmacokinetics of buspirone extendedrelease tablets: a single-dose study. J Clin Pharmacol 2001; 41(7): 783-9.
146. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996; 32(3): 335-42.
147. Feiger AD, Heiser JF, Shrivastava RK, et al. Gepirone extendedrelease: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003; 64(3): 243-9.
148. Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol 2005; 25(1): 79-84.
149. Amsterdam JD, Brunswick DJ, Gibertini M. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial. J Psychiatr Res 2004; 38(3): 259-65.
150. Robinson DS, Sitsen JM, Gibertini M. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clin Ther 2003; 25(6): 1618-33.
151. Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23(5): 427-52.
152. Cao BJ, Rodgers RJ. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 1997; 36(8): 1089-97.
153. Bianchi G, Caccia S, Della Vedova F, Garattini S. The alpha 2- adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur J Pharmacol 1988; 151(3): 365-71.
154. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59(6): 530-7.
155. Schloesser RJ, Chen G, Manji HK. Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int Rev Neurobiol 2007; 77: 143-78.
156. Hirschfeld RM, Keck PE, Jr., Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, doubleblind, placebo-controlled trial. Am J Psychiatry 2004; 161(6): 1057-65.
157. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160(4): 741-8.
158. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57(9): 841-9.
159. Niufan G, Tohen M, Qiuqing A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008; 105(1-3): 101-8.
160. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28(1): 13-20.
161. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9- week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15(1): 75-84.
162. Keck PE, Jr., McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003; 12(4): 655-62.
163. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20(4): 536-46.
164. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-42.
165. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009; 112(1-3): 36-49.
166. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidolcontrolled study. Br J Psychiatry 2009; 194(1): 40-8.
167. Keck PE, Jr., Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67(4): 626-37.
168. Keck PE, Jr., Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68(10): 1480-91.
169. Vieta E, T'Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165(10): 1316-25.
170. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159(7): 1146-54.
171. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59(1): 62-9.
172. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6(3): 213-23.
173. Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 2008; 64 (Suppl 2): S16-29.
174. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000; 62(1): 63-88.
175. Lledo A. Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism Relat Disord 2000; 7(1): 51-58.
176. Jankovic J. Natural course and limitations of levodopa therapy. Neurology 1993; 43(2): S14-S17.
177. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342(20): 1484-91.
178. Hagan JJ, Middlemiss DN, Sharpe PC, Poste GH. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol Sci 1997; 18(5): 156-63.
179. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003; 20(11): 847-55.
180. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004; 18(11): 733-46.
181. Hauser RA, Bronzova J, Sampaio C, et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced parkinson's disease. Eur Neurol 2009; 62(1): 40-8.
182. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26(6): 439-44.
183. Lader M. Antiparkinsonian medication and pathological gambling. CNS Drugs 2008; 22(5): 407-16.
184. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287(4): 455-63.
185. Hitzeman N, Rafii F. Dopamine agonists for early Parkinson disease. Am Fam Physician 2009; 80(1): 28-30.
186. Mengod G, Villaro MT, Landwehrmeyer GB, et al. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int 1992; 20 (Suppl): 33S-43S.
187. Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90(2-3): 231-59.
188. Mercuri NB, Saiardi A, Bonci A, et al. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997; 79(2): 323-7.
189. Bennett JP, Jr., Piercey MF. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999; 163(1): 25-31.
190. Lozano AM, Lang AE, Hutchison WD, Dostrovsky JO. New developments in understanding the etiology of Parkinson's disease and in its treatment. Curr Opin Neurobiol 1998; 8(6): 783-90.
191. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002; 58 (4 Suppl 1): S1-8.
192. Ahlenius S, Ericson E, Florvall L, Jimenez P, Hillegaart V, Wijkstrom A. In vivo characterization of novel full and partial 2-(4- aminophenyl)-N,N-dipropylethylamine dopamine D(2) receptor agonists. Eur J Pharmacol 2000; 394(2-3): 247-53.
193. Kannari K, Kurahashi K, Tomiyama M, et al. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 2002; 54(2): 133-7.
194. Krosser S, Neugebauer R, Chassard D, Kovar A. Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. Biopharm Drug Dispos 2007; 28(7): 339-47.
195. Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009; 15(6): 445-52.
196. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130(Pt 7): 1819-33.
197. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008; 7(10): 927-38.
198. Wang S, Zhang QJ, Liu J, et al. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5- HT(1A) receptor stimulation in the rat. Neuroscience 2009; 159(2): 850-61.
199. Frechilla D, Cobreros A, Saldise L, et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001; 39(4): 288-96.
200. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003; 60 (4): 601-5.
201. Temel Y, Boothman LJ, Blokland A, et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by highfrequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci U S A 2007; 104(43): 17087-92.
202. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999; 14(9): 711-8.
203. Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Curr Psychiatry Rep 2002; 4(1): 69-73.